HELIOS UNDERWRITING PLC

Declaration of Voting Results & Voting Rights Announcements • Feb 1, 2024

National Storage Mechanism | Additional information

RNS Number : 6013B

Helios Underwriting Plc

01 February 2024

1 February 2024

Helios Underwriting plc

("Helios" or the "Company")

Total Voting Rights

As at 31 January 2024 the Company's issued share capital consisted of 77,945,833 ordinary shares of £0.10 each ("Ordinary Shares"). The Company holds 3,200,689 Ordinary Shares in treasury. The total number of voting rights in the Company is therefore 74,745,144. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Helios Underwriting plc

Martin Reith - Chief Executive Officer                    +44 (0)7720 292 505

Nigel Hanbury - Executive Deputy Chairman        +44 (0)7787 530 404  

Arthur Manners - Chief Financial Officer                                +44 (0)7754 965 917

Deutsche Numis (Nomad and Broker)                                   

Giles Rolls / Charles Farquhar                                     +44 (0)20 7260 1000

Buchanan (PR)

Helen Tarbet / George Beale                                      +44 (0)7872 604 453

+44 (0)20 7466 5111

About Helios

Helios provides a limited liability direct investment into the Lloyd's insurance market and is quoted on the London Stock Exchange's AIM market (ticker: HUW). Helios trades within the Lloyd's insurance market writing approximately £501m of capacity for the 2024 account. The portfolio provides a good spread of business being concentrated in property & casualty insurance and reinsurance. For further information please visit www.huwplc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRWPURCGUPCGMG